Zika triggered travel warnings, with pregnant women being urged to postpone non-essential trips to affected countries during a surge in cases which revealed the mosquito-borne virus could cause birth defects.
Governments, academic laboratories, and pharmaceutical companies invested heavily in stopping the virus.
The committed public health efforts paid off, with Brazil declaring an end to its Zika emergency in May after a drop in cases.
However the World Health Organisation has warned that tens of millions of people could still be infected in the Americas in the coming years.
There are currently no licensed vaccines or therapeutics available to combat Zika, although a $100m US government-led clinical trial is underway.
Now, researchers from Arizona State University (ASU) in the US have developed the world’s first plant-based Zika vaccine.
They believe this vaccine could be “more potent, safer, and cheaper to produce” than the other medicines being developed.
“Our vaccine offers improved safety and potentially lowers the production …